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Abstract
Background: Occult hepatitis C virus infection (OCI) is a recently described phenomenon characterized by undetectable
levels of HCV-RNA in serum/plasma by current laboratory assays, with identifiable levels in peripheral blood mononuclear
cells (PBMCs) and/or liver tissue by molecular tests with enhanced sensitivity. Previous results from our group showed an
OCI prevalence of 3.3% in a population unselected for hepatic disease. The present study aimed to evaluate OCI prevalence
in a larger cohort of infectious liver disease-free (ILDF) subjects. Clinical follow-up of OCI subjects was performed to
investigate the natural history of the infection.
Methods and Findings: 439 subjects referred to a Turin Blood Bank for phlebotomy therapy were recruited. They included
314 ILDF subjects, 40 HCV-positive subjects and 85 HBV-positive subjects, of whom 7 were active HBV carriers. Six subjects
(4/314 ILDF subjects [1.27%] and 2/7 active HBV carriers [28%]) were positive for HCV-RNA in PBMCs, but negative for
serological and virological markers of HCV, indicating OCI. HCV genotypes were determined in the PBMCs of 3/6 OCI
subjects two had type 1b; the other had type 2a/2c. OCI subjects were followed up for at least 2 years. After 12 months only
one OCI persisted, showing a low HCV viral load (3.736101 UI/ml). By the end of follow-up all OCI subjects were negative for
HCV. No seroconversion, alteration of liver enzyme levels, or reduction of liver synthesis occurred during follow-up.
Conclusions: This study demonstrated the existence of OCI in ILDF subjects, and suggested a high OCI prevalence among
active HBV carriers. Follow-up suggested that OCI could be transient, with a trend toward the decrease of HCV viral load to
levels undetectable by conventional methods after 12–18 months. Confirmation studies with a longer follow-up period are
needed for identification of the OCI clearance or recurrence rates, and to characterize the viruses involved.
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Introduction
In the past years, a new form of hepatitis C virus (HCV)
infection has been identified and defined as ‘‘occult’’ HCV
infection (OCI) [1–3]. OCI is characterized by: i. detection of
HCV-RNA in liver tissue alone, or in liver tissue and/or
peripheral blood mononuclear cells (PBMCs); ii. consistently
undetectable HCV-RNA in serum [4–5].
OCI has two possible sets of clinical features: negativity for both
serum anti-HCV antibodies (anti-HCV) and HCV-RNA with
abnormal liver function tests, or positivity for serum anti-HCV
and no detectable HCV-RNA with normal liver enzyme levels
years after spontaneous, or therapy-induced resolution of HCV
infection [2,4–7]. We have also reported on OCI in subjects
without evidence of hepatic disease [8]. The reason why HCV-
RNA is not detectable in the serum of OCI patients is unknown.
One hypothesis is that the number of circulating viral particles in
OCI patients is too low to be detected by conventional molecular
techniques [9]. To overcome this limitation, the sensitivity of
detection methods has been improved by introducing ultracentri-
fugation of plasma, or mitogen in vitro stimulation of PBMCs
[2,10]. However, despite these efforts, HCV-RNA was not
detected in these patients.
HCV has been shown to infect, and replicate in, both liver tissue
and PBMCs of OCI patients, as indicated by the antigenomic
HCV-RNA strand found in these patients [11]. In spite of its
relatively recent identification, OCI has been investigated in
different geographical regions [12], with emerging implications in
different clinical scenarios. Barril and colleagues found an OCI
prevalence of 45% in 109 haemodialysis patients [13], and the
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same group of investigators claimed there was a potential trans-
mission risk of OCI [14], as they found a high OCI prevalence
among relatives of OCI patients, comparable to that found among
family members of patients with chronic HCV infection.
Conversely, other authors did not find OCI in immune-suppressed
subjects [15–16], in 28 onco-haematological [17] patients, or in 26
kidney-transplant patients [18].
Discordant OCI results in other HCV-related clinical manifes-
tations, such as mixed cryoglobulinemia [19–20], autoimmune
disorders [4] and non-Hodgkin lymphoma [21], have been
published, and suggest that more studies in this field are needed.
To our knowledge, no data have been published on OCI in
patients with hepatitis B virus (HBV) infection.
The OCI prevalence in the general population is presently
unknown. We previously reported on the occurrence of OCI in
a population unselected for hepatic disease: in a sample of 276
apparently healthy Italian subjects who were negative for
serological markers of HCV and viraemia, some 3% harboured
HCV-RNA in their PBMCs [8]. In order to further investigate this
unexpected finding, the present study aimed to evaluate the OCI
prevalence in a broader series of infectious liver disease-free
(ILDF) subjects, through testing of serial samples and long-term
clinical follow-up. We also investigated HCV genotypes, HCV-
RNA replication potential, and clearance or persistence of the
virus in PBMCs from serial blood samples.
Results
Characteristics of the 439 subjects included in the study (336
men and 103 women, ratio 3:1, mean age: 67 years) are shown in
Table 1. The study population was selected for diseases treated by
phlebotomy therapy (hereditary hemochromatosis, iron overload,
porphyria cutanea tarda, secondary erythrocytosis, polycythemia
vera and arteriopathy), and was composed of subjects with a high
mean age and a wide age range (26–88 years); the subgroup of
subjects treated for iron overload were the youngest (mean age
61.8 years). We found altered alanine aminotransferase (.50 IU/
L for men and .35 IU/L for women) and aspartate aminotrans-
ferase (.40 IU/L for men and .25 IU/L for women) levels in 57
men and 35 women respectively, with a higher frequency in the
HCV-positive control group than in the ILDF group (p,0.0001;
data not shown).
None of the 439 subjects tested positive for markers of human
immunodeficiency virus (HIV1–2) infection (HIV1–2 antibodies in
serum and HIV-RNA in plasma).
Three groups of subjects were generated based on viral infection
and serological pattern: ILDF, HCV-positive control group and
HBV-positive group.
The ILDF group included 314 subjects negative for markers of
both HBV and HCV infection in serum (hepatitis B surface
antigen, HBsAg and anti-HCV) and plasma (HBV-DNA and
HCV-RNA), and for markers of previous HBV contact (antibodies
against hepatitis B surface antigen, anti-HBs; antibodies against
hepatitis B core antigen, anti-HBc) (Figure 1).
The HBV-positive group included 85 subjects who were
negative for previous or active HCV infection (anti-HCV/HCV-
RNA). Seventy-eight of the subjects in the HBV-positive group
showed a resolved HBV infection (negative for HBsAg/HBV-
DNA), while seven still had an active HBV infection (positive for
HBsAg/HBV-DNA) (Figure 1). These seven subjects (all men;
mean age 68.7 years) were also placed into an ‘‘active HBV
infection subgroup’’.
Among the seven subjects in the active HBV infection subgroup,
five were HBsAg-positive in serum and HBV-DNA-positive in
plasma, and one was HBsAg-positive but HBV-DNA-negative
because he was on interferon treatment. The remaining subject in
the active HBV infection subgroup was positive for HBV-DNA in
plasma but negative for HBsAg in serum (the serological pattern of
occult HBV infection).
The HCV-positive control group included 40 subjects (34 men
and 6 women; mean age 64.4 years) who were anti-HCV positive
by a RIBA assay, 38 of whom were already known to be infected.
(Figure 1). Eighteen of them also showed markers of a resolved
HBV infection (positive for anti-HBc; negative for HBsAg/HBV-
DNA).
No subjects in the active HBV infection subgroup or the HCV-
positive control group were taking interferon treatment during the
study period.
HCV-RNA was detectable in the plasma of 34 out of the 40
subjects in the HCV-positive control group. None of the subjects
in the ILDF group or the HBV-positive control group were HCV-
RNA-positive in plasma. The absence of HCV-RNA in these
subjects was confirmed after ultracentrifugation of plasma.
Of the 34 subjects with HCV-RNA in plasma, genotyping of the
isolated HCV-RNA showed that 18 (53%) had genotype 1b, three
(9%) had genotype 1a, three (9%) had genotype 2, six (18%) had
genotype 2a/2c, two (6%) had genotype 4d, one (3%) had
genotype 3a and one (3%) had genotype 1a/1b (data not shown).
In addition, 30 out of the 34 subjects who were HCV-RNA-
positive in plasma were also HCV-RNA-positive in PBMCs
(Table 2), and the genotypes found therein were the same as those
found in plasma, save one subject who had HCV 1a in plasma and
1b in PBMCs.
A total of six subjects who were negative for all markers of HCV
infection in serum and plasma, were positive for HCV-RNA in
PBMCs by gel electrophoresis and by real-time PCR (Table 2),
thereby revealing OCI: four (1.27%) of the 314 subjects in the
ILDF group and two (28%) of the seven subjects in the active HBV
infection subgroup.
HCV genotypes in PBMCs were determined for three of the six
OCI subjects, resulting in HCV type 1b in two cases, and 2a/2c in
another (Table 3). Three samples failed to be genotyped due to
weak detection of the PCR fragment.
At the end of recruitment, all six OCI subjects were followed up
until March 2011 (Table 4). Liver function tests were not altered in
any of the OCI subjects. Liver enzyme levels remained within
normal ranges for five OCI subjects throughout the study period.
Only one of the six OCI subjects showed slightly abnormal alanine
aminotransferase levels (54 IU/L) at recruitment, which sub-
sequently decreased to normal levels during follow-up. Negativity
for anti-HCV in serum and HCV-RNA in plasma persisted during
follow-up for all subjects, and was further confirmed after
ultracentrifugation of plasma. When PBMCs from follow-up
specimens were tested by reverse-transcription PCR assay,
negative results were found at gel electrophoresis evaluation,
which has known limits in the detection of low density (,25 ng)
amplicons. All 42 follow-up samples from the six OCI subjects
were then retested by real-time PCR, and three turned out to be
positive (Table 4).
HCV viral load was evaluated both in the plasma and PBMCs
of the HCV-positive control group, and in the PBMCs of all
samples collected from OCI subjects at recruitment and at follow-
up, and the results reported in IU/ml. At recruitment, in the 34
subjects positive for HCV-RNA in plasma, the HCV viral load
therein ranged from 4.606103 IU/ml to 7.736103 IU/ml, with
a median of 1.736107 IU/ml. The amounts at the 25th and 75th
percentiles were 1.516104 and 5.366106 IU/ml, respectively. In
buffy-coats the viral load ranged from 1.116101 IU/ml to
OCI in an Infectious Liver Disease-Free Population
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2.496106 IU/ml, with a median of 2.256105 IU/ml. The values
at the 25th and 75th percentiles were 1.196104 IU/ml and
5.306105 IU/ml, respectively (data not shown).
HCV viral loads for the six OCI subjects are shown in Table 3.
The buffy-coat samples that were positive at baseline showed low
viral loads, with a median of 2.406102 IU/ml (range from
6.476101 IU/ml to 2.396103 IU/ml). Ten months after re-
cruitment only two subjects were still positive for HCV-RNA in
PBMCs by quantitative PCR, with HCV-RNA levels of
2.516102 IU/ml and 2.056101 respectively (subjects 1 and 3,
Table 4). Twelve months after recruitment only one subject
(subject 3) was still positive (HCV viral load of 3.736101 IU/ml),
but became negative by 25 months of follow-up (Table 4).
To investigate the potential transmission risk of OCI, we
performed mitogen in vitro stimulation of about 56106 PBMCs
from the six OCI subjects with Interleukin-2 and phytohaemoag-
glutinin for 7 days, and assessed the release of HCV virions in the
supernatant. PBMCs from one subject in the HCV-positive
control group, with an HCV viral load of 3.706105 IU/ml, and
from two subjects in the ILDF group, were analogously stimulated
and used as positive and negative controls, respectively. The
positive control sample released the virus into the supernatant
(1.996101 IU/ml). Only one OCI sample (subject 5, PBMCs
HCV viral load 3.246102 IU/ml) showed a quantifiable amount
of HCV genome in the culture medium by real-time PCR,
corresponding to 2.26101 IU/ml. The negative controls and all
other recruitment and follow-up samples from OCI subjects failed
to show the virus in the supernatant.
Discussion
Little is known about the prevalence of OCI, its natural
history, potential transmission risk and impact in the general
population. Detection of HCV-RNA in PBMCs in the absence
of serological markers of HCV has been almost exclusively
reported for patients with liver disease or immunosuppressed
patients [1,13,22]. However, we recently found an OCI
prevalence of 3.3% in a population of 276 subjects unselected
for hepatic disease [8]. Here, in a broader series of subjects
submitted to phlebotomy therapy for different disorders un-
related to infectious liver disease, we again confirmed the
occurrence of OCI, with a prevalence of 1.27%. Furthermore
we observed a high OCI prevalence (28%) (p = 0.004) in the
active HBV infection subgroup. Markers of previous HBV
infection were detected in several of our study subjects (103
total: 85 in the HBV-positive group, and 18 in the HCV-
positive control group) (Figure 1). Among them, 20 (19.4%) had
an HCV infection (18 overt and 2 OCI). When we considered
subjects with HCV infection (46 total: 40 overt and 6 OCI) we
found 20 subjects (43.5%) that had been infected with HBV.
The association observed in the present study between HCV
and HBV infection is not a completely new finding. Occult HBV
infection has also been described, with different prevalences in
different studies, in HCV carriers [23], and chronic co-infection
with the two viruses has been proposed as a factor that increases
the risk of neoplastic progression [24].
If we consider the subjects with either resolved or active HBV
infection, the prevalence of OCI was 1.94% (2/103), comparable
with that found in the ILDF group. In this context HBV contact
does not seem to be a risk factor for OCI. Conversely, the high
prevalence of OCI (2/7) that we found in the active HBV infection
subgroup is very intriguing and needs to be thoroughly in-
vestigated. Nevertheless, even though we found a statistically
significant difference (p = 0.0008) within this small subgroup, any
statement that active HBV infection is strongly associated with
OCI must be considered with caution. One possible explanation
for the high prevalence we observed is that active HBV infection
could have a modulating effect on the immune system, facilitating
the persistence of HCV infection in PBMCs. The fact that among
all OCI subjects, the two with HBV showed the longest persistent
infection (subject 3), and the highest viral load in PBMCs (subject
6), respectively, could support this hypothesis.
The OCI prevalence found in the ILDF group was lower than
that found in our previous study (1.27% vs 3.3%). In addition, the
Table 1. Characteristics of the study subjects.
INFECTIVE LIVER DISEASE-FREE
GROUP (ILDF) (N=314)
HCV-POSITIVE CONTROL
GROUP (N=40) HBV-POSITIVE GROUP (N=85)
DIAGNOSIS
Hereditary hemochromatosis 38 7 9
Iron overload 28 16 8
Porphyria cutanea tarda 1 3 1
Secondary erythrocytosis 103 5 30
Polycythemia vera 140 9 36
Arteriopathy 4 0 1
AGE
Range (mean) years 26–82 (65.25) 41–85 (64.4) 36–88 (66.7)
26–40 years 16 0 2
41–55 years 55 14 7
56–70 years 132 10 34
71–85 years 107 16 40
.86 years 4 0 2
GENDER
Male/Female 235/79 34/6 67/18
doi:10.1371/journal.pone.0043541.t001
OCI in an Infectious Liver Disease-Free Population
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latter population was not screened for markers of HBV infection,
and because there is an intermediate prevalence of HBV infection
in Italy that varies widely from region to region, we are not able to
estimate how many subjects in our previous study were HBV
carriers. Though the number of subjects was limited, considering
the high OCI prevalence detected in the active HBV infection
subgroup of the present study (28%), the higher prevalence found
Figure 1. Flow chart of distribution of subjects enrolled in the study based on presence of serological markers of human
immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV). Subjects positive for HBsAg and/or HBV-DNA were
considered carriers of HBV. Subjects positive for anti-HCV and HCV-RNA or anti-HCV positive confirmed by the RIBA assay even though negative for
HCV-RNA were considered HCV infection. Subjects HBsAg negative, anti-HBc positive with or without anti-HBs and HBV-DNA negative with normal
alanine aminotransferase levels were considered previously HBV infected and naturally immunized. Abbreviations: anti-HIV, HIV antibodies; anti-HCV,
antibodies against HCV; HBsAg, hepatitis B surface antigen; anti-HBc, hepatitis B core antibodies; pos, positive; neg, negative.
doi:10.1371/journal.pone.0043541.g001
OCI in an Infectious Liver Disease-Free Population
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in our previous study could be explained by the presence of some
HBV carriers.
No single HCV genotype was predominant in the present study;
instead different genotypes were present in both the HCV-positive
control group (1a, 1b, 2a, 3a, 4d) and in OCI subjects (1b, 2a/2c).
Similar results have been reported in other case-series of subjects
with spontaneous, or treatment-induced resolution of viral
infections [2]. A different HCV genotype in PBMCs and plasma
was found in only one subject from the HCV-positive control
group. An analogous feature has been described by several authors
[25–27], who reported that a proportion of HCV-infected subjects
harboured genotypes in their PBMCs that could not be detected in
their plasma. An explanation of these differences in the
distribution of genotypes may be related to the presence of viral
variants due to mutations that confer distinct cellular tropism
[26,27]. Studies of the hypervariable E2 region of HCV showed
that specific variants are frequent, particularly in B lymphocytes
and monocytes [25,27].
A strength of our study was the follow-up of OCI subjects to
partially investigate the natural history of the infection. The six
subjects with OCI showed a very low HCV viral load in PBMCs,
detected through highly sensitive methods, which in some cases
did not even allow us to trace the genotype. Only two of these OCI
subjects (subjects 1 and 3) had detectable HCV infection in
PBMCs at 11 and 13 months of follow-up, respectively, demon-
strating a persistent infection. There were two OCI subjects with
HBV infection: one showed the longest persistent infection (subject
3), and the other had the highest viral load in PBMCs (subject 6) of
all the OCI subjects, suggesting a potential interference between
the two infections.
In all the other subjects (subjects 2, 4, 5 and 6) we failed to
demonstrate OCI persistence, since none were HCV-RNA-
positive in PBMCs at 9, 11, 18 and 25 months of follow-up,
respectively, after initial detection. Moreover, after mitogen
in vitro stimulation of PBMCs, no HCV was detectable, which
points more to the actual clearance of the virus than to
a fluctuating replication.
This is in accordance with recently published data describing 16
OCI subjects, detected after successful response to antiviral
treatment, who cleared the virus from PBMCs at 6 to 12 months
of follow-up [28]. Furthermore the apparent clearance of viremia
in PBMCs in our subjects was not drug-influenced because none of
our OCI subjects was undergoing interferon or ribavirin therapy
during the study. At variance with our results is a study conducted
by Castillo and colleagues, which reported on the follow-up of 37
subjects with a diagnosis of OCI who presented abnormal liver
function of unknown aetiology for a minimum of 12 months [29].
The authors described the persistence of very low levels of HCV-
RNA intermittently detected in PBMCs and in the serum of these
patients during a mean follow-up of 55.7 months. In our subjects
HCV viremia was never detected and HCV-RNA in PBMCs was
never detected in follow-up samples after its disappearance. This
pattern is more consistent with a possible clearance of the infection
than with a persistent infection with replication flares, although the
latter cannot be excluded. A longer follow-up is needed for
confirmation.
HCV-RNA monitoring in serial PBMCs and serum improved
the identification of OCI, and this approach has been suggested as
a useful method for the diagnosis of OCI when a liver biopsy is not
available [29].
The novelty of our findings lies in the transient detection of OCI
for a mean follow-up time of 23 to 35 months in a population
naı¨ve for hepatic viral infections and without abnormal liver
function.
Evolution of molecular assays and ultracentrifugation methods
to improve the monitoring of HCV infection presently ensures
detection of low levels of HCV-RNA. However, the relevance of
HCV-RNA detection in PBMCs alone is poorly understood,
although the proven ability of HCV to replicate in these cells
[11,30] raises questions about the potential transmission risk to
other cell types (i.e., liver), or to other individuals through blood
transfusions or haemodialysis. Indeed, the possible transmission of
infection between OCI carriers and people undergoing haemo-
dialysis has been described [13]. Among all enrolment and follow-
Table 2. HCV-RNA detection in plasma and PBMCs.
PLASMA HCV-RNA HCV-RNA PBMCs POSITIVE HCV-RNA PBMCs NEGATIVE TOTAL
Infective liver disease-free group
Positive 0 0 0
Negative 4 310 314
Total 4 310 314
HCV-positive control group
Positive 30 4 34
Negative 0 6 6
Total 30 10 40
HBV-positive group
Positive 0 0 0
Negative 0 85 85
Total 0 85 85
active HBV infection subgroup
Positive 0 0 0
Negative 2 5 7
Total 2 5 7
Abbreviations: HCV, hepatitis C virus; PBMC, peripheral blood mononuclear cells; HBV, hepatitis B virus.
doi:10.1371/journal.pone.0043541.t002
OCI in an Infectious Liver Disease-Free Population
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up PBMCs in the present study, in only one sample was it possible
to identify HCV-RNA in the supernatant after mitogen in vitro
stimulation, showing the ability of the virus to replicate. Whether
the HCV-RNA detected in supernatant represents competent
viruses released from PBMCs is only presumable, but this could
represent a potential transmission risk to different compartments,
such as liver cells. Nevertheless no clinical evidence of liver
involvement was seen in our subjects during follow-up. Moreover,
for the aforementioned subject, no subsequent PBMC sample
allowed for viral detection, suggesting that replication capability
was not sufficient to maintain a persistent infection. The inability
of the other samples to show detectable viraemia in the
supernatant could be due to the very low number of virions
originally infecting the PBMCs in our subjects, or to a low virus
replication efficiency due to peculiar characteristics of the viruses.
Further studies that perform full-length sequences of these viruses
are needed to help show whether genomic mutations could cause
this kind of impaired replication.
In conclusion, we observed an OCI prevalence of 1.27% in 314
ILDF subjects with no signs of active or previous viral hepatic
infection, and an unexpectedly high OCI prevalence in HBV
carriers. OCI seems unable to affect liver cells, or to have an
impact on liver function, nor does it seem to produce an antibody
immune response. It seems to be a transient infection that can
potentially be cleared within 18 months of its detection. In this
scenario, it seems unlikely that OCI could be easily transmitted
between humans, although confirmation and family studies with
a longer follow-up are needed to monitor viral clearance and
potential transmission risk.
We are planning to continue follow-up of HCV-negative
subjects and OCI subjects at 12-month intervals to investigate
whether periodical recurrences of HCV infection with low viral
loads occur in PBMCs, and if cumulative prevalence in the general
population is higher than we detected.
Materials and Methods
Study Series
Between April 2008 and September 2009, we recruited a total
of 439 subjects referred to the Blood Bank of the S. Giovanni
Battista Hospital in Turin, Italy for phlebotomy therapy as
treatment for different diseases (Table 1). A peripheral blood
sample for PBMC separation (about 14 mL) was collected at
enrolment into two tubes containing EDTA. Subjects were tested
for liver enzyme levels, the presence of markers of HBV infection
(HBsAg, anti-HBs, and anti-HBc), anti-HCV and HIV1–2
antibodies in serum samples, and for HBV-DNA, HCV-RNA
and HIV-RNA in plasma. Subjects with OCI were followed-up for
23 to 35 months, during which they were prospectively tested at
least six times for liver enzyme levels, anti-HCV in serum, and
HCV-RNA in plasma and PBMCs.
The first follow-up sample was used to perform a complete
hepatic synthesis, including dosage of total plasma protein,
albumin, cholesterol, total and fractionated bilirubin, prothrombin
time, partial thromboplastin time and international normalized
ratio. All blood parameters were evaluated by standardized
methods. Signed consent forms were obtained at the time of
recruitment, and the study was approved by the local ethics
committee (CEI, Comitato Etico Interaziendale S. Giovanni
Battista Hospital and CTO-Maria Adelaide Hospital, Turin,
Italy).
Plasma and buffy-coats were separated from 10 mL of whole
blood and stored immediately at 280uC. PBMCs were isolated
from the remaining 4 mL of whole blood using the Ficoll-
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Hypaque density gradient (Lonza, Walkersville, Maryland, USA).
The PBMC pellet was then washed twice in phosphate-buffered
saline (pH 7.4), and resuspended in RPMI 1640 medium
supplemented with penicillin, streptomycin, glutamine and 50%
heat-inactivated Foetal Calf Serum (FCS); an equal volume of
a solution including RPMI 1640 (30%), dimethyl sulfoxide
(DMSO, 20%), and FCS (50%) was added for alive freezing of
PBMCs at 280uC.
Detection of Markers of Hepatitis Infection in Serum
Samples
HBsAg, anti-HBs, anti-HBc and anti-HCV testing in serum was
performed by chemiluminescent microparticle immunoassay
(CMIA) (Architect system, ABBOTT Diagnostic Division, Abbot
Park, Illinois, USA); HIV1–2 antibodies were detected using
CMIA for the simultaneous qualitative detection of HIV-p24
antigen and HIV1–2 antibodies (Architect system).
Genomic Viral Detection in Plasma
Presence of HBV-DNA, HCV-RNA and HIV-RNA in plasma
was detected using a multiplex transcription-mediated amplifica-
tion technology (Procleix Ultrio on Tigris, Chiron, Emeryville,
California, USA) with a 95% detection limit of 8–10 IU/ml for
HBV-DNA, 3.01–3.17 IU/ml for HCV-RNA and 20–30 IU/ml
for HIV-RNA.
HCV-RNA Extraction and Detection in PBMCs
Total RNA was isolated from 150 mL of buffy-coat using the SV
Total RNA Isolation System (Promega, Madison, Wisconsin,
USA) and EXTRAgene (Amplimedical, Turin, Italy), respectively,
according to the manufacturer’s instructions. In 150 mL of buffy-
coat a cell number ranging from 16106 to 16107 was found.
Buffy-coats were washed three times using SV RNA Red Blood
Cell Lysis Solution (Promega) in order to avoid carry-over of
inhibitors. Adequacy of extracted RNA was checked through
reverse transcription of 5 mL to cDNA (Reverse Transcription
System, Promega) and amplification of a 171 bp fragment of the
beta-actin gene as previously reported [8].
Detection of HCV-RNA was performed by a commercial
reverse-transcription nested-PCR system (Alfa Wasserman,
Milan, Italy) using the primers targeting the 59UTR region of
the HCV genome included in the kit as previously described
[8]. The presence of an 187 bp amplification fragment indicated
HCV-RNA positivity in the sample. Synthetic HCV-RNA
corresponding to the 59UTR region, HCV-negative human
serum, and RNA-free samples were included as positive and
negative controls, respectively, in each PCR run. The sensitivity
of the test was up to 50 genome equivalents (6 IU/ml). Repeat
testing was performed on all positive samples for confirmation
in different PCR amplification runs to exclude the possibility of
contamination.
HCV-RNA Detection in Ultracentrifuged Plasma Samples
Plasma samples from HCV-RNA-negative subjects were
subjected to ultracentrifugation to allow detection of low amounts
of viral particles. Two mL of stored plasma were ultracentrifuged
for 3 hours at 100,000 g at 4uC, and RNA extracted from the
resulting pellet was used for HCV-RNA detection.
HCV Viral Load
Ten mL of purified RNA were used to evaluate HCV viral
load by amplification in real-time PCR (artusHHCV RG RT-
PCR kit, Qiagen, Hilden, Germany) on the iCycler iQTM Real-
Time PCR Detection System (Bio-Rad, Hercules, California,
USA) as follows: one cycle of reverse transcription at 50uC for
30 minutes; 13 minutes at 95uC followed by 50 cycles of
denaturation for 30 seconds at 95uC; annealing for 1 minute at
55uC; and extension for 30 seconds at 72uC. Each amplification
run included negative and positive controls for HCV-RNA to
monitor the performance of the methods, as well as a curve of
calibrators (104, 103, 102, and 101 IU/mL) purchased with the
kit. The sensitivity of the test was 34 IU/ml. A further point of
1 IU/mL (about 3.4 IU/ml) was created by 10-fold dilution of
the 101 calibrator to improve reliable quantification of low viral
loads.
The threshold cycle (Ct) was calculated by a software for data
analysis with an automatic baseline setting (BioRad). An external
calibration curve was generated automatically by plotting the Ct
values against the logarithm of the IU numbers of the serial
calibrators carrying the HCV genome. For quantification, the
absolute IU number of unknown samples was calculated by
plotting the Ct values against the logarithm of the standard curve.
The sensitivity of the method was 1021 IU. HCV viral load was
expressed in IU/ml according to the following formula: Result
(IU/mL) = [Result (IU/mL)6Elution Volume (mL)]/Sample Vol-
ume (mL).
HCV Genotyping
HCV genotyping was performed in plasma samples using the
VERSANTH HCV Genotype 2.0 kit (Siemens Medical Solution
Diagnostic, Tarrytown, New York, USA) according to the
manufacturer’s instructions. This system is a line-probe assay
Table 4. Timing of blood sampling and HCV-RNA results on PBMCs during follow-up of OCI subjects.
2008 2009 2010 2011
N April May Jul Feb Mar Apr May June Jul Aug Sep Oct Nov Dec Jan Feb Mar
1 1.556102 2.516102 N N N N N N N
2 6.476101 N N N N N N N
3 1.406102 2.056101 3.736101 N N N N N
4 1.716103 N N N N N
5 3.246102 N N N N N N
6 2.396103 N N N N
NOTE: Normal characters indicate baseline samples. Italics indicates follow-up samples.
Abbreviations: N, negative result.
doi:10.1371/journal.pone.0043541.t004
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based on reverse hybridization. It identifies HCV genotypes 1 to 6
and subtypes ‘‘a’’ and ‘‘b’’ of genotype 1; it has a sensitivity of
96%, and a concordance with sequence-based phylogenetic
analysis of 100%.
HCV genotyping for buffy-coat-derived PCR amplicons was
performed by direct sequencing, after excision from the gel of the
187 bp 59UTR fragment and purification with the ‘‘PCR Clean-
up Gel Extraction Kit’’ (Macherey-Nagel, Dueren, Germany).
Direct sequencing was carried out using the Big Dye Terminator
Cycle Sequencing Ready Reaction Kit (Applera, Monza, Italy),
and sequence analysis was performed with the ABI 310 automated
capillary system (Applera), following the manufacturer’s instruc-
tions. Sequences were analysed using BLAST Software (http://
www.ncbi.nlm.nih.gov/BLAST). All HCV genotypes were defined
with a query coverage of $98%, analysing at least 170 nucleotides
of the target sequence.
Mitogen in vitro Stimulation of PBMCs
To investigate the replication and potential transmission risk of
OCI, we performed a 7-day mitogen in vitro stimulation of PBMCs
collected from OCI subjects both at recruitment and during
follow-up, and assessed and quantified the release of HCV virions
in the supernatant. PBMCs from one HCV-positive subject with
an HCV viral load of 3.706105 IU/ml, and from two HCV-
negative subjects were analogously stimulated to be used as
positive and negative controls, respectively. Fresh or stored alive
PBMCs were cultured in vitro in RPMI supplemented with 10%
FCS, under mitogen stimulation with Interleukin-2 (20 U/mL)
and phytohaemoagglutinin (5 mg/mL), according to previously
described methods [2]. About 106106 fresh or 56106 thawed
from storage PBMCs were incubated with mitogens at 37uC with
5% CO2 for 7 days. Afterwards, cells were harvested and counted,
and supernatant after ultracentrifugation was investigated for
HCV-RNA detection by reverse-transcription nested-PCR.
Statistical Analysis
We analysed three separate groups of subjects: the ILDF group
included all subjects negative for serological markers of both HBV
and HCV infection (HBsAg, anti-HBc, anti-HBs, and anti-HCV;
HBV-DNA and HCV-RNA), the HCV-positive control group
included subjects with confirmed HCV infection (anti-HCV-
positive), the HBV-positive group included anti-HBc-positive
subjects and the active HBV infection subgroup included subjects
with markers of HBV infection in serum (HBsAg or HBV-DNA)
(Figure 1, Table 1).
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